Hi peony, guess the annual report is the summary of the previous 12 months and the direction of the company for the future, the quarterlies more relevant to the previous 3 months, imo.
Only postive/s from next quarterly: significant revenue, less cash burn, not sure whether anything as important as immunotherapies clarification, funding issues etc will come out, unless via announcements.
Same as last hsv-2 update, next quarterly needs to be outstanding: ordinary/alright not going to cut it, imo.
Latter will possibly see this sp continue to languish.
Answers from WP - a good read, page-299
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.68 |
Change
0.680(4.53%) |
Mkt cap ! $331.4M | |||
| Open | High | Low | Value | Volume |
| $14.90 | $15.75 | $14.85 | $431.9K | 28.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $15.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.95 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |